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                                                  ABSTRACT 
 
AIMS AND OBJECTIVES:   
               1. TO STUDY THE CLINICAL PROFILE OF HYPERTHYROIDISM 
AT STANLEY HOSPITAL 
    2.TO STUDY ECHOCARDIOGRAPHIC FINDINGS IN THESE 
PATIENTS 
MATERIALS AND METHODS 
  PLACE OF STUDY: 
           DEPARTMENT OF GENERAL MEDICINE,  ENDOCRINOLOGY OPD, 
MEDICAL OPD, MEDICAL WARDS,   STANLEY MEDICAL COLLEGE AND 
HOSPITAL, CHENNAI. 
  DURATION: 
           NOV 2013 TO NOV 2014. 
  SAMPLE SIZE: 60 
  STUDY DESIGN: 
           PROSPECTIVE  OBSERVATIONAL STUDY 
 
  PATIENT SELECTION: 
ANY PATIENT COMING WITH  SYMPTOMS SUGGESTIVE OF 
HYPERTHYROID TO ENDOCRINOLOGY OPD, MEDICAL OPD 
MEDICAL WARDS.  
 
  EXCLUSION CRITERIA: 
             PATIENTS WITH  KNOWN HEART DISEASE.  
 METHODOLOGY: 
                        Patients coming with symptoms suggestive of hyperthyroidism to 
OPDs from November 2013 to November 2014 are included in the study. Patients 
will be subjected to symptom analysis , clinical examination , laboratory 
investigations and Echocardiogram. The final analysis will be made at the end of 
the study to achieve the forementioned goals. 
                                                     CONCLUSION 
 Hyperthyroidism is more common in females of younger age group 
commonly in third decade of life. 
 Hyperthyroid patients mostly presents with neck swelling and palpitation and 
menstrual irregularities forms the significant complaint in my study. 
 Hyperthyroid has significant effect on cardiac activity. It is a high output state. 
Causing systolic and diastolic dysfunction , pulmonary hypertension, left 
ventricle chamber enlargement , heart failure. 
 Hyperthyroidism-related cardiac changes was largely asymptomatic and 
reversible after restoration to an euthyroid state. So hyperthyroidism should 
be considered as the reversible cause in cardiac morbidity. 
 As a non-invasive method, echocardiography can play a vital role in 
recognizing the cardiac pathology in hyperthyroidism as well as to follow up 
the response to therapy. 
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                                             INTRODUCTION 
 
Hyperthyroidism is a condition where thyroid gland produces excessive amount 
of thyroid hormone. 
 
Most common causes are Grave’s disease, toxic multinodular goiter, toxic 
adenoma,subacute thyroiditis, drugs, secondary hyperthyroidism 
 
Clinical features were palpitation, neck swelling, nervousness, increased 
appetite & loss of weight, hair loss, heat intolerance, menstrual irregularities, 
loose stools and easy fatguibility.On  examining , patient may have goiter, 
tremors, eye signs, gynacomastia. 
 
Lab investigation will reveal low TSH and high T3 and T4.Thyroid imaging, 
radioactive iodine uptake study, Thyroid biopsy, Thyroid autoantibodies were 
other tests to find out the etiology of the disease. 
 
Main stay of treatment include antithyroid drugs, radioactive ablation, surgery. 
 
Cardiovascular manifestations of hyperthyroidism were tachycardia, atrial 
fibrillation, increased cardiac output, systolic and diastolic dysfunction, 
worsening of heart failure, systolic murmur. 
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                             REVIEW OF LITERATURE 
 
                    The thyroid gland is the largest organ specialized for endocrine 
function in the human body. The major function of the thyroid follicular cells is 
to secrete a sufficient amount of thyroid hormones, primarily 3,5,3′,5′-l-
tetraiodothyronine (T4), and a lesser quantity of 3,5,3′-l-triiodothyronine (T3). 
Thyroid hormones promote normal growth and development and regulate a 
number of homeostatic functions, including energy and heat production. In 
addition, the parafollicular cells of the human thyroid gland secrete calcitonin, 
which is important in calcium homeostasis. 
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                                   ANATOMY & HISTOLOGY 
 
                   The thyroid gland originates as an outpouching in the floor of the 
pharynx, which grows downward anterior to the trachea, bifurcates, and forms a 
series of cellular cords.  The lateral lobes of the thyroid connected by a thin 
isthmus formed from those tiny balls or follicles. The origin of the gland at the 
base of the tongue is evident as the foramen cecum. The course of its downward 
migration is marked by the thyroglossal duct, remnants of which may persist in 
adult life as thyroglossal duct cysts. These are mucus-filled cysts, lined with 
squamous epithelium, and are usually found in the anterior neck between the 
thyroid cartilage and the base of the tongue. A remnant of the caudal end of the 
thyroglossal duct is found in the pyramidal lobe, attached to the isthmus of the 
gland. 
                 The isthmus of the thyroid gland is located just below the cricoid 
cartilage, midway between the apex of the thyroid cartilage (“Adam's apple”) 
and the suprasternal notch. Each lobe is pear-shaped and measures about 2.5–4 
cm in length, 1.5–2 cm in width, and 1–1.5 cm in thickness. The weight of the 
gland in the normal individual, as determined by ultrasonic examination, varies 
depending on dietary iodine intake, age, and body weight but in adults is 
4 
 
approximately 10–20 g. Upward growth of the thyroid gland is limited by the 
attachment of the sternothyroid muscle to the thyroid cartilage; however,  
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posterior and downward growth is unhampered, so that thyroid enlargement, or 
goiter, will frequently extend posteriorly and inferiorly or even substernally. 
 
 
 
 
 
 
                             DEVELOPMENT OF THYROID GLAND 
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BLOOD SUPPLY OF THYROID 
                  The thyroid gland is highly vascular organ . External carotid artery 
gives rise to superior thyroid artery , Thyrocervical trunk gives to inferior  
thyroid artery.and third and rare branch thyroid ima artery from brachiocephalic 
artery. 
                    Superior,middle and inferior thyroid veins are formed from venous 
plexus on thyroid gland surface and on front of trachea. Superior and middle 
drains in internal jugular and inferior in innominate vein..; in hyperthyroidism, 
the blood flow to the gland is markedly increased, and a whistling sound, or 
bruit, may be heard over the lower poles of the gland and may even be felt in 
the same areas as a vibration, or thrill. Other important anatomic considerations 
include the two pairs of parathyroid glands that usually lie behind the upper and 
middle thyroid lobes and the recurrent laryngeal nerves, which course along the 
trachea behind the thyroid gland. 
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                             BLOOD SUPPLY OF THYROID GLAND 
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HISTOLOGY 
                 On microscopic examination, the thyroid gland is found to consist of 
a series of follicles of varying sizes. The follicles contain a pink-staining 
material (with hematoxylin-eosin stain) called “colloid” and is enclosed by 
thyroid epithelium. Tissue culture studies suggest that each follicle may 
represent an individual clone of cells. These cells become columnar when 
stimulated by TSH and flattened when resting . The follicle cells synthesize 
thyroglobulin, which is extruded into the lumen of the follicle. The biosynthesis 
of T4 and T3 occurs within thyroglobulin at the cell-colloid interface.Surface of 
follicle gives rise to many microvilli.; these are involved in endocytosis of 
thyroglobulin, which is then hydrolyzed in the cell to release thyroid hormones                                                                                                                                                                                                                                                              
 
            HISTOLOGY OF THYROID GLAND 
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                                                   PHYSIOLOGY 
 
STRUCTURE OF THYROID HORMONES 
                    Thyroid hormones are unique in that they contain 59–65% of the 
trace element iodine. The iodinated thyronines are derived from iodination of 
the phenolic rings of tyrosine residues in thyroglobulin to form mono- or 
diiodotyrosine, which are coupled to form T3 or T4 . 
 
IODINE METABOLISM 
                  Iodine enters the body in food or water in the form of iodide or 
iodate ion, the iodate ion being converted to iodide in the stomach. In the course 
of millennia, iodine was extracted from the soil and washed down into the 
oceans, so that in mountainous and inland areas the supply of iodine may be 
quite limited, whereas the element is plentiful in coastal areas. The thyroid 
gland concentrates and traps iodide and synthesizes and stores thyroid hormones 
in thyroglobulin, which compensates for the scarcity of iodine 
                 The recommendations of the World Health Organization for optimal 
daily iodide intake are as follows: for adults, 150 µg; during pregnancy and 
lactation, 200 µg; for the first year of life, 50 µg; for ages 1–6, 90 µg; and for 
ages 7–12, 120 µg. If iodide intake is below 50 µg/d, the gland is unable to 
maintain adequate hormonal secretion, and thyroid hypertrophy (goiter) and 
hypothyroidism result. In the United States, the average daily iodide intake 
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increased from a range of 100–200 µg/d in the 1960s to 240–740 µg/d in the 
1980s. This was largely due to the introduction of iodate as a dough conditioner, 
though other sources of dietary iodine included iodized salt, vitamin and 
mineral preparations, iodine-containing medications, and iodinated contrast 
media. In the 1990s, bromine salts replaced iodine in the baking industry, and 
iodine intake has fallen considerably, indicating the need for continued 
monitoring. Iodide is rapidly absorbed from the alimentary tract and distributed 
in extracellular fluids as well as in salivary, gastric, and breast secretions. 
Although the concentration of inorganic iodide in the extracellular fluid pool 
will vary directly with iodide intake, extracellular fluid I- is usually quite low 
because of the rapid clearance of iodide from extracellular fluid by thyroidal 
uptake and renal clearance. In the example shown, the basal I- concentration in 
extracellular fluid is only 0.6 µg/dl, or a sum of 150 µg of I- in an extracellular 
pool of 25 L despite a daily oral intake of 500 µg I-. In the thyroid gland there is 
active transport of I- from the serum across the basement membrane of the 
thyroid cell . The thyroid gland takes up about 115 µg of I- per 24 hours, or, in 
this example, about 18% of the available I-. About 75 µg of I- is utilized for 
hormone synthesis and stored in thyroglobulin; the remaining iodide goes to 
extracellular fluid. The thyroid pool of organified iodine is very large, averaging 
8–10 mg, and represents a store of hormone and iodinated tyrosines, protecting 
the organism against a period of iodine lack. From this storage pool, about 75 
µg of hormonal iodide is released into the circulation daily. This hormonal 
11 
 
iodide is mostly bound to serum thyroxine-binding proteins, forming a 
circulating pool of about 600 µg of hormonal I- (as T3 and T4). From this pool, 
about 75 µg of I- as T3 and T4 is taken up and metabolized by tissues. About 60 
µg of I- is returned to the iodide pool and about 15 µg of hormonal I- is 
conjugated with glucuronide or sulfate in the liver and excreted into the stool.. 
In the USA, the 24-hour thyroidal radioiodine uptake has decreased from about 
40–50% in the 1960s to about 8–30% in the 1990s because of increased dietary 
iodide intake. 
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Processes of synthesis and iodination of thyroglobulin and its reabsorption 
and digestion  
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THYROID HORMONE SYNTHESIS AND SECRETION 
                       The production of thyroid hormone by the thyroid gland involves 
six major steps: (1) active carriage of iodide to the basement membrane into the 
thyroid cell (iodide trapping); (2) iodide oxidation & thyroglobulin iodination 
by tyrosyl residues; (3) T3 and T4 formation bycoupling of iodotyrosine in 
thyroglobulin ; (4) release of free iodothyronines and iodotyrosines by 
proteolysis; (5) iodotyrosines in the thyroid cell will be deiodonised and 
remanant iodide will be reused ; and (6) intrathyroidal 5′-deiodination of T4 to 
T3. 
                      Thyroid hormone synthesis involves a unique glycoprotein, 
thyroglobulin, and an essential enzyme, thyroperoxidase (TPO). 
THYROGLOBULIN 
             Thyroglobulin is a large glycoprotein molecule containing 5496 amino 
acids, with a molecular weight of about 660,000 and a sedimentation coefficient 
of 19S. It contains about 140 tyrosyl residues and about 10% carbohydrate in 
the form of mannose, N-acetylglucosamine, galactose, fucose, sialic acid, and 
chondroitin sulfate. The 19S thyroglobulin compound is a dimer of two 
identical 12S subunits, but small amounts of the 12S monomer and a 27S 
tetramer are often present. The iodine content of the molecule can vary from 
0.1% to 1% by weight. In thyroglobulin containing 0.5% iodine (26 atoms of 
iodine per 660-kDa molecule), there would be 5 molecules of monoiodotyrosine 
(MIT), 4.5 molecules of diiodotyrosine (DIT), 2.5 molecules of  thyroxine (T4), 
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and 0.7 molecules of triiodothyronine (T3). About 75% of the thyroglobulin 
monomer consists of repetitive domains with no hormonogenic sites. There are 
four tyrosyl sites for hormonogenesis on the thyroglobulin molecule: One site is 
located at the amino terminal end of the molecule, and the other three are 
located in a sequence of 600 amino acids at the carboxyl terminal end. There is 
a surprising homology between this area of the thyroglobulin molecule and the 
structure of acetylcholinesterase, suggesting conservation in the evolution of 
these proteins. 
 
THYROIDAL PEROXIDASE 
                  Thyroidal peroxidase is a membrane-bound glycoprotein with a 
molecular weight of about 102,000 and a heme compound as the prosthetic 
group of the enzyme. This enzyme mediates both the oxidation of iodide ions 
and the incorporation of iodine into tyrosine residues of thyroglobulin. 
Thyroidal peroxidase is synthesized in the rough endoplasmic reticulum (RER). 
After insertion into the membrane of RER cisternae, it is transferred  to the 
apical cell surface through Golgi elements and exocytic vesicles. Here, at the 
cell colloid interface, it is available for iodination and hormonogenesis in 
thyroglobulin. Thyroidal peroxidase biosynthesis is stimulated by TSH 
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IODIDE TRANSPORT (THE IODIDE TRAP) 
                      I- is transported across the basement membrane of the thyroid cell 
by an intrinsic membrane protein called the Na+/I- symporter (NIS). At the 
apical border, a second I- transport protein called pendrin moves iodine into the 
colloid where it is involved in hormonogenesis . The NIS derives its energy 
from Na+-K+ ATPase, which drives the transport process. This active transport 
system allows the human thyroid gland to maintain a concentration of free 
iodide 30–40 times that in plasma. The NIS is stimulated by TSH and by the 
TSH receptor-stimulating antibody found in Graves' disease. It is saturable with 
large amounts of iodide and inhibited by ions such as ClO4
-, SCN-, NO3
-, and 
TcO4
-. Some of these ions have clinical utility. Sodium perchlorate will 
discharge nonorganified iodide from the NIS and has been used to diagnose 
organification defects  and in the treatment of iodide-induced hyperthyroidism. 
Sodium pertechnetate Tc99m, which has a 6-hour half-life and a 140-keV 
gamma emission, is used for rapid visualization of the thyroid gland for size and 
functioning nodules. Pendrin, encoded by the Pendred syndrome gene (PDS), is 
a transporter of chloride and iodide. Mutations in the PDS gene have been found 
in patients with goiter and congenital deafness (Pendred's syndrome). Although 
iodide is concentrated by salivary, gastric, and breast tissue, these tissues do not 
organify or store I- and are not stimulated by TSH. 
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                                      IODINE METABOLISM 
 
 
 
17 
 
IODINATION OF TYROSYL IN THYROGLOBULIN 
                         Within the thyroid cell, at the cell-colloid interface, iodide is 
rapidly oxidized by H2O2, catalyzed by thyroperoxidase, and converted to an 
active intermediate which is incorporated into tyrosyl residues in thyroglobulin. 
H2O2 is probably generated by a dihydronicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase in the presence of Ca2+; this process is stimulated 
by TSH. The iodinating intermediate may be iodinium ion (I+), hypoiodate, or 
an iodine-free radical. The site of iodination at the apical (colloid) border of the 
thyroid cell can be demonstrated by autoradiography. Thyroidal peroxidase will 
catalyze iodination of tyrosyl molecules in proteins other than thyroglobulin, 
such as albumin or thyroglobulin fragments. However, no thyroactive hormones 
are formed in these proteins. The metabolically inactive protein may be released 
into the circulation, draining thyroidal iodide reserves. 
 
COUPLING OF IODOTYROSYL RESIDUES IN THYROGLOBULIN 
                           The coupling of iodotyrosyl residues in thyroglobulin is also 
catalyzed by thyroperoxidase. It is thought that this is an intramolecular 
mechanism involving three processes: (1) iodotyrosyl residues is oxidized to an 
activated form by thyroperoxidase; (2) in thyroglobulin, coupling of  
iodotyrosyl residues to form a quinol ether intermediate; and (3) iodothyronine 
is formed by division of quinol ether. For this process to occur, the dimeric 
structure of thyroglobulin is essential: Within the thyroglobulin molecule T4  is 
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formed by combining of two  DIT molecules, and T3 by combining an MIT & 
DIT. Thiocarbamide drugs—particularly propylthiouracil, methimazole, and 
carbimazole—are potent inhibitors of thyroperoxidase and will block thyroid 
hormone synthesis . These drugs are clinically useful in the management of 
hyperthyroidism. 
 
PROTEOLYSIS OF THYROGLOBULIN & THYROID HORMONE 
SECRETION 
                    Rough endoplasmic reticulum secretes lysosomes and golgi 
apparatus packs it.These structures, surrounded by membrane, have an acidic 
interior and are filled with proteolytic enzymes, including proteases, 
endopeptidases, glycoside hydrolyases, phosphatases, and other enzymes. At the 
cell-colloid interface, colloid is engulfed into a colloid vesicle by a process of 
macropinocytosis or micropinocytosis and is absorbed into the thyroid cell. The 
lysosomes then fuse with the colloid vesicle and  thyroglobulin gets hydrolysed 
and it releases MIT,DIT,T3,T4 , peptide fragments, and amino acids. T3 and T4 
are released into the circulation, while DIT and MIT are deiodinated and the I- is 
conserved. Thyroglobulin with a low iodine content is hydrolyzed more rapidly 
than thyroglobulin with a high iodine content, which may be beneficial in 
geographic areas where natural iodine intake is low. The mechanism of 
transport of T3 and T4 through the thyroid cell is not known, but it may involve 
a specific hormone carrier. TSH stimulates secretion of throid hormone by 
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activating adenylyl cyclase and by the cAMP , suggesting that it is cAMP-
dependent.  
                Large amount of iodide restricts thyroglobulin proteolysis  like 
lithium , which, as lithium carbonate, is used for the treatment of bipolar 
disorders. A little quantity of  thyroglobulin which is not hydrolysed is secreted 
from the thyroid cell; this is markedly elevated in certain situations such as 
subacute thyroiditis, hyperthyroidism, or TSH-induced goiter . Thyroglobulin 
(perhaps modified) may also be synthesized and released by certain thyroid 
malignancies such as papillary or follicular thyroid cancer and may be useful as 
a marker for metastatic disease. 
 
INTRATHYROIDAL DEIODINATION 
                    MIT and DIT formed during the synthesis of thyroid hormone are 
deiodinated by intrathyroidal deiodinase . This enzyme is an NADPH-
dependent flavoprotein found in mitochondria and microsomes. It targets only o 
MIT and DIT but not on T3 and T4. The iodide released is  reutilized for 
hormone synthesis. The 5′-deiodinase that converts T4 to T3 in peripheral tissues 
is also found in the thyroid gland. In situations of iodide deficiency, the activity 
of this enzyme may increase the amount of T3 secreted by the thyroid gland, 
increasing the metabolic efficiency of hormone synthesis. 
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  THYROID HORMONE SYNTHESIS IN A THYROID FOLLICLE 
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CONTROL OF THYROID FUNCTION 
                   The thyroid gland development and function and thyroid hormones 
effects are managed by four mechanisms : (i) TSH , thyroid stimulating 
hormone synthesized by thyrotropic releasing hormone called as hypothalamic 
pituitary thyroid axis. Thyroid gland is then stimulated by TSH for its growth; 
(2)T3 & T4 actions are controlled by peripheral and pituitary deiodinases ; 
(3)thyroid gland has its own autoregulation for iodine demand;(4)Thyroid  
function is controlled by TSH receptor autoantibodies. In addition, the effects of 
T3 may be modified by the status of the T3 receptor (repressor or activation) and 
potentially by nonthyroidal T3 receptor agonists or antagonists. 
                                  
 
                THE HYPOTHALAMIC-HYPOPHYSIAL-THYROIDAL AXIS 
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THYROTROPIN-RELEASING HORMONE 
                      Thyrotropin-releasing hormone (TRH) is a tripeptide, 
pyroglutamyl-histidyl-prolineamide, is formed in hypothalamus 
supraventricular & supraoptic nulei neurons. After formation it is kept in 
median eminence of hypothalamus. Then it travels to pituitary portal vein 
system to pituitary gland anterior for controlling synthesis of TSH secretion. 
The gene for human preproTRH, located on chromosome 3, contains a 3.3-kb 
transcription unit that encodes six TRH molecules. The gene also encodes other 
neuropeptides that may be biologically significant. In the anterior pituitary 
gland,  TSH and prolactin are synthesized by binding of TRH to receptors in 
thyrotrophs and prolactin synthesizing cells. TRH response is decreased by 
thyroid hormone by slow process whereas estrogen increases TRH response by 
increasing sensitivity in pituitary. 
                    The response of the pituitary thyrotroph to TRH is bimodal: First, it 
stimulates release of stored hormone; and second, it stimulates gene activity, 
which increases hormone synthesis. The TRH receptor (TRH-R) is a member of 
the seven-transmembrane-spanning, GTP-binding, protein-coupled receptor 
family. The TRHR gene is located on chromosome 8. Large glycoprotein 
hormones such as TSH and LH bind to the extracellular portions of their 
receptors, but TRH, a small peptide, binds to the transmembrane helix 3 of the 
TRH-R. After binding to its receptor on the thyrotroph, TRH activates a G 
protein, which in turn activates phospholipase c to hydrolyze 
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phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate 
(IP3). IP3 stimulates the release of intracellular Ca
2+, which causes the first burst 
response of hormone release.  
                        Simultaneously, there is generation of 1,2-diacylglycerol, which 
activates protein kinase C, thought to be responsible for the second and 
sustained phase of hormone secretion. The increases in intracellular Ca2+ and in 
protein kinase C may be involved in increased transcription of TSH. For 
ithyroid hormone full biologic activity it should be glycosylation of TSH  which 
is stimulated by TRH. 
 
THYROTROPIN 
                Thyroid-stimulating hormone, or thyrotropin (TSH), is a glycoprotein 
synthesized and secreted by the thyrotrophs of the anterior pituitary gland. It has 
a molecular weight of about 28,000 and is composed of two noncovalently 
linked subunits, α and β. The α subunit is common to the two other pituitary 
glycoproteins, FSH and LH, and also to the placental hormone hCG; the β 
subunit is different for each glycoprotein hormone and confers specific binding 
properties and biologic activity. The human α subunit has an apoprotein core of 
92 amino acids and contains two oligosaccharide chains; the TSH β subunit has 
an apoprotein core of 112 amino acids and contains one oligosaccharide chain. 
The α and β subunit amino acid chains of TSH each form “cysteine knot” by 
joining three coils which are interrupted. Mutations of the amino acids in either 
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chain can result in either decreased or increased TSH activity. Glycosylation 
takes place in the rough ER and the Golgiapparatus of the thyrotroph, where 
glucose, mannose, and fucose residues and terminal sulfate or sialic acid 
residues are linked to the apoprotein core. The function of these carbohydrate 
residues is not entirely clear, but it is likely that they enhance TSH biologic 
activity and modify its metabolic clearance rate. For example, deglycosylated 
TSH will bind to its receptor, but its biologic activity is markedly decreased and 
its metabolic clearance rate is markedly increased. 
                          Thyroid hormone production is controlled by mainly TSH. This 
is attained by binding of TSH with its receptor called TSH-R which is unique 
and then it causes triggering of cAMP . The human TSH receptor (TSH-R) gene 
is located on chromosome 14q3. The TSH-R is a single-chain glycoprotein 
containing 764 amino acids. Like the TRH receptor of the anterior pituitary, the 
TSH-R in the thyroid follicular cell is a member of the seven-membrane 
spanning, GTP-binding protein-coupled receptor family. Structurally, it can be 
divided into two subunits: subunit A, containing 397 amino acids, representing 
the ectodomain which is involved in ligand binding; and subunit B, which 
includes the intramembrane and intracellular portion of the receptor involved in 
action of thyroid development,  hormone production, and its release. The TSH-
R is unique in that it has binding sites not only for TSH but also for TSH 
receptor antibody, which are found in patients with autoimmune 
hyperthyroidism (Graves' disease), and also for autoantibodies that bind to the 
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TSH receptor and block the action of TSH (TSH-R Ab [block]). These 
antibodies are also found in hypothyroidism and some thyroiditis 
                      Mutations in the TSH-R have been associated with either 
spontaneous activation of the receptor and clinical hyperthyroidism or with 
resistance to TSH. Activating mutations involving the B subunit of the TSH-R 
have been found in solitary autonomous adenomas and in multinodular goiters 
as well as in rare cases of sporadic familial hyperthyroidism. Resistance to TSH 
due to mutations in either subunit of the receptor is related to high TSH levels. 
                   
                     EFFECTS OF TSH ON THE THYROID CELL 
      
                              TSH has many actions on the thyroid cell. Most of its actions 
are mediated thrgh the G protein-adenylyl cyclase-cAMP system, but activation 
of the phosphatidylinositol (PIP2) system with increase in intracellular calcium 
may also be involved. The major actions of TSH include the following: 
 
A. CHANGES IN THYROID CELL MORPHOLOGY 
                  TSH rapidly induces pseudopods at the cell-colloid border, 
accelerating thyroglobulin resorption. Colloid content is diminished. 
Intracellular colloid droplets are formed and lysosome formation is stimulated, 
increasing thyroglobulin hydrolysis. 
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B. CELL GROWTH 
                Individual thyroid cells increase in size ; vascularity is increased; and, 
over a period of time, thyroid enlargement, or goiter, develops. 
C. IODINE METABOLISM 
               TSH stimulates every steps of iodide metabolism, from increased 
iodide uptake and transport to increased iodination of thyroglobulin and 
increased secretion of thyroid hormones. The increase in cAMP mediates 
increased iodide transport, while PIP2 hydrolysis and increased intracellular 
Ca2+ stimulate the iodination of thyroglobulin. The TSH effect on iodide 
transport is biphasic: Initially, it is depressed (iodide efflux); and then, after a 
lag of several hours, iodide uptake is increased. The efflux of iodide may be due 
to the rapid increase in hydrolysis of thyroglobulin with release of hormone and 
leakage of iodide out of the gland. 
D. OTHER EFFECTS OF TSH 
                    Other effects include increase in mitochondrial RNA for 
thyroglobulin and thyroperoxidase, with an increase in incorporation of I- into 
MIT, DIT, T3 and T4; and increased lysosomal activity, with increased secretion 
of T4 and T3 from the gland. There is also increased activity of type 1 5′-
deiodinase, conserving intrathyroidal iodine. 
                    TSH has still other effects on the thyroid gland, including icrease of 
glucose uptake, usage of oxygen, synthesis of carbondioxide, and oxidation of 
glucose is increased by urea cycle and HMP shunt. There is accelerated turnover 
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of phospholipids and stimulation of production of purine & pyrimidine 
precursors, with more production of RNA & DNA.. 
SERUM TSH 
                Normally, only α subunit and intact TSH are present in the serum. 
The level of α subunit is about 0.5–2 µg/L; it is elevated in old aged women 
who attained their menopause and in with TSH producing pituitary mass . The 
normal level of TSH ranges from 0.5 to 5 m U / L ; it is elevated in 
hypothyroidism and reduced in hyperthyroidism, whether endogenous or from 
excessive oral intake of thyroid hormones. The plasma half-life of TSH is half 
an hour, and the daily synthesis rate is about 40 to150 mU/d. 
CONTROL OF PITUITARY TSH PRODUCTION 
                        The important factors controlling the synthesis and release of 
Thyroid stimulating hormone are in level of intrathyrotroph T3,  controls mRNA 
for Thyroid stimulating hormone formation & its release; and TRH. 
                    TSH synthesis and release are inhibited by high serum levels of T4 
and T3 (hyperthyroidism) and stimulated by low levels of thyroid hormone 
(hypothyroidism).  Some  hormones and drugs inhibit TSH secretion like 
somatostatin, dopamine, bromocriptine, and glucocorticoids.  During illness 
there will be suppression of TSH, and there may be a rebound rise in TSH as the 
patient recovers. The magnitude of these effects is variable; thus, the drugs 
mentioned above will suppress serum TSH, but it will usually be detectable. In 
contrast, hyperthyroidism will turn off TSH secretion entirely.  
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These observations are important clinically in interpreting serum TSH levels in 
patients receiving these medications. Secondary hypothyroidism is one due to 
pathology in hypothalamus or pituitary, where as tertiary hypothyroidism is due 
to damage of TRH producing neurons. 
OTHER THYROID STIMULATORS & INHIBITORS 
                          The thyroid follicle has a rich supply of capillaries that carry 
noradrenergic nerve fibers from the superior cervical ganglion and acetylcholine 
esterase-positive nerve fibers derived from the vagal nodose and thyroid 
ganglia. The parafollicular C cells secrete both calcitonin and calcitonin gene-
related peptide (CGRP).  In addition, growth factors such as insulin, IGF-I, and 
EGF and the autocrine actions of prostaglandins and cytokines may modify 
thyroid cell growth and hormone production. However, it is not yet clear how 
important these effects are in clinical situations. 
ROLE OF PITUITARY & PERIPHERAL DEIODINASES 
                         T4  to T3 is changed by pituitary type 2 5′-deiodinas at the brain 
and pituitary, providing the main source of intracellular T3. Its increased activity 
in hypothyroidism  provides in maintaining cerebral intracellular T3 in the view 
of reducing serum T4 concentrations. In hyperthyroidism, the reduction in its 
action provides in preventing overload of pituitary and neural cells with thyroid 
hormone. In contrary, type 1 5′-deiodinase is reducing in hypothyroidism, 
securing T4, and more in hyperthyroidism, increasing the T4 metabolism. 
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THYROIDAL AUTOREGULATION 
                      Autoregulation may be defined as the capacity of the thyroid 
gland to modify its function to adapt to changes in the availability of iodine, 
independent of pituitary TSH. Thus, humans can maintain normal thyroid 
hormone secretion with iodide intakes varying from 50 µg to several milligrams 
per day. Some of the effects of iodide deficiency or excess are discussed above. 
The major adaptation to low iodide intake is the preferential synthesis of T3 
rather than T4, increasing the metabolic effectiveness of the secreted hormone. 
Iodide excess, on the other hand, inhibits many thyroidal functions, including 
Iodide transport, production of cAMP, formation of H2O2, hormone production 
& its release and bondage of TSH and TSH –R Ab to its receptor. Some of these 
effects may be mediated by the formation of intrathyroidal iodinated fatty acids. 
The ability of the normal thyroid to “escape” from these inhibitory effects 
(Wolff-Chaikoff effect) allows the gland to continue to secrete hormone despite 
a high dietary iodide intake. It is important to note that this is different from the 
therapeutic effect of iodide in the treatment of Graves' disease. Here, the high 
levels of iodide inhibit thyroglobulin endocytosis and lysosomal activity, 
decreasing thyroid hormone release and lowering circulating hormone levels. In 
addition, the inhibition of TSH-R Ab [stim] activity reduces the vascularity of 
the gland, with beneficial consequences during surgery. This effect is also 
transient, lasting about 10 days to 2 weeks. 
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AUTOIMMUNE REGULATION 
                  B lymphocytes are the major one in thyroid regulation by producing   
TSH receptor antibodies which can block the action of TSH or it can simulate 
TSH action by binding to various areas on the TSH receptor. 
 
                       THE ACTION OF THYROID HORMONES 
 
1. THE THYROID HORMONE RECEPTOR 
                      Thyroid hormones, T3 and T4, circulate in plasma largely bound to 
protein but in equilibrium with the free hormone. It is the free hormone that is 
transported, either by passive diffusion or by specific carriers, through the cell 
membrane, through the cell cytoplasm, to bind to a specific receptor in the cell 
nucleus. Inside  the cell, T4 is changed to T3 by 5’ deiodinase, implicating that 
T4 is a proactive and T3 the functional form of the hormone. In the human, there 
are two genes for the thyroid hormone receptor, alpha and beta. TRα is located 
on chromosome 17 and TRβ on chromosome 3. Each gene produces at least two 
products, TRα 1 and 2 and TRβ 1 and 2. Each has three domains: a ligand-
independent domain at the amino terminal, a centrally located DNA binding 
area with two cysteine-zinc “fingers,” and a ligand-binding domain at the 
carboxyl terminal. Note that TRα2 does not bind T3 and may actually inhibit T3 
action.  
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The concentration of these receptors in tissue varies with the stage of 
development and the tissue. For example, the brain contains mostly TRα, the 
liver mostly TRβ, and cardiac muscle contains both. The binding affinity of T3 
analogs is directly proportionate to the biologic activity of the analog. Point 
mutations in the ligand-binding domain of the TRβ gene are responsible for the 
syndrome of generalized resistance to thyroid hormone. 
                     The thyroid hormone receptors may bind to the specific thyroid 
hormone response element (TRE) sites on DNA even in the absence of T3 (—
unlike the steroid hormone receptors). The TREs are located near—generally 
upstream with respect to the start of transcription—to the promoters where 
transcription of specific thyroid hormone-responsive genes is initiated. T3 
binding to the receptors results in stimulation—in some cases inhibition—of the 
transcription of these genes with consequent changes in the levels of the 
mRNAs transcribed from them. The changes in mRNA levels alter the levels of 
the protein product of these genes. These proteins then mediate the thyroid 
hormone response. These receptors often function as heterodimers with other 
transcription factors such as the retinoid X receptor and the retinoic acid 
receptor 
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2. PHYSIOLOGIC EFFECTS OF THYROID HORMONES 
                               The transcriptional effects of T3 characteristically 
demonstrate a lag time of hours or days to achieve full effect. These genomic 
actions result in a number of effects, including those on tissue growth, brain 
maturation, and increased heat production and oxygen consumption, which is 
due in part to increased activity of Na+-K+ ATPase and in part to production of 
increased beta-adrenergic receptors. Some actions of T3 are not genomic, such 
as reduction of pituitary type 2 5′-deiodinase and increase in glucose and amino 
acid transport. Some specific effects of thyroid hormones are summarized in 
what follows. 
EFFECTS ON FETAL MATURATION 
                      At fetal life of 11 weeks itself TSH and thyroid hormones will 
begin their functions. Because of the high placental content of type 3 5-
deiodinase, most maternal T3 and T4 are inactivated in the placenta, and very 
little free hormone reaches the fetal circulation. This little quantity of available 
hormoneis essential for fetal brain maturation. However, after 11 wks of 
pregnancy, the fetus is largely dependent on its own thyroidal secretion. 
Although some fetal growth occurs in the absence of fetal thyroid hormone 
secretion, brain development and skeletal maturation are markedly impaired, 
resulting in cretinism (mental retardation and dwarfism). 
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EFFECTS ON OXYGEN CONSUMPTION, HEAT PRODUCTION, & FREE 
RADICAL FORMATION 
                          T3 increases O2 consumption and heat production in part by 
stimulation of Na+-K+ ATPase in all tissues except the brain, spleen, and testis. 
This contributes to the increased basal metabolic rate (O2 consumption by the 
whole animal at rest) and the increased sensitivity to heat in hyperthyroidism—
and the converse in hypothyroidism. Thyroid hormones also decrease 
superoxide dismutase levels, resulting in increased superoxide anion free radical 
formation. This may contribute to the deleterious effects of chronic 
hyperthyroidism. 
CARDIOVASCULAR EFFECTS 
                   T3 induces transcription of α part of myosin heavy chain and 
depresses β heavy chain, making more cardiac muscle contractility. In addition 
T3  fastens transcription of Ca
2+ ATPase in the sarcoplasmic reticulum, raising 
diastolic tone of the heart; changes isoforms of Na+-K+ ATPase genes; and 
raises beta-adrenergic receptors and the concentration of G proteins. So , thyroid 
hormones have marked positive inotropic and chronotropic effects on the heart. 
This makes , there is high cardiac output & hear rate in hyperthyroidism 
whereas low in hypothyroidism. 
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SYMPATHETIC EFFECTS 
                       Thyroid hormones raises more number of beta-adrenergic 
receptors in heart & skeletal muscle, adipose tissue, and lymphocytes. It  also 
slows the myocardial alpha-adrenergic receptors.  They also may accelerate 
catecholamine action at a postreceptor site. Thus, response to catecholamines is 
more pronounced  in hyperthyroidism, and treatment with beta-adrenergic 
blocking agents may be very helpful in controlling tachycardia and arrhythmias. 
PULMONARY EFFECTS 
                Thyroid hormones maintain normal oxygen and carbondioxide 
demand by keeping respiratory centre active.  In severe hypothyroidism, 
hypoventilation occurs, occasionally requiring assisted ventilation. 
HEMATOPOIETIC EFFECTS 
                           The increased cellular demand for O2 in hyperthyroidism leads 
to increased production of erythropoietin and increased erythropoiesis. 
However, blood volume is usually not increased because of hemodilution and 
increased red cell turnover. Thyroid hormones increase the 2,3-
diphosphoglycerate content of erythrocytes, so that it makes more displacement 
of  O2  from haemoglobin to tissues. The reverse occurs in hypothyroidism. 
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GASTROINTESTINAL EFFECTS 
                      Thyroid hormones stimulate gut motility, which can result in 
increased motility and diarrhea in hyperthyroidism and slowed bowel transit and 
constipation in hypothyroidism. This may also contribute to the modest weight 
loss in hyperthyroidism and weight gain in hypothyroidism. 
SKELETAL EFFECTS 
                     Thyroid hormones stimulate increased bone turnover, increasing 
bone resorption and, to a lesser degree, bone formation. Thus, chronic 
hyperthyroidism may result in significant osteopenia and, in severe cases, 
modest hypercalcemia, hypercalciuria, and increased excretion of urinary 
hydroxyproline and pyridinium cross-links. 
NEUROMUSCULAR EFFECTS 
                         Although thyroid hormones stimulate increased synthesis of 
many structural proteins, in hyperthyroidism there is increased protein turnover 
and loss of muscle tissue, or myopathy. This may be associated with 
spontaneous creatinuria. Increased reflexes in hyperthyroidism is due to fast 
muscle contraction and relaxation or the reverse in hypothyroidism. Thyroid 
hormones are essential for normal development and function of the central 
nervous system, and failure of fetal thyroid function results in severe mental 
retardation. In the adult, hyperactivity in hyperthyroidism and sluggishness in 
hypothyroidism can be striking. 
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EFFECTS ON LIPID & CARBOHYDRATE METABOLISM 
                        Hyperthyroidism increases liver glucose production and 
glycogen breakdown as well as gut glucose absorption. Thus, hyperthyroidism 
will exacerbate underlying diabetes mellitus. Cholesterol synthesis and 
degradation are both increased by thyroid hormones. The latter effect is due 
largely to an increase in the hepatic low-density lipoprotein (LDL) receptors, so 
that cholesterol levels decline with thyroid overactivity. Lipolysis is also 
increased, releasing fatty acids and glycerol. Conversely, cholesterol levels are 
elevated in hypothyroidism. 
ENDOCRINE EFFECTS 
               Thyroid hormones increase the metabolic turnover of many hormones 
and pharmacologic agents. Increases the half life of cortisol. The production rate 
of cortisol will increase in the hyperthyroid patient with normal adrenal 
function, thus maintaining a normal circulating hormone level. However, in a 
patient with adrenal insufficiency, the development of hyperthyroidism or 
thyroid hormone treatment of hypothyroidism may unmask the adrenal disease. 
Ovulation may be impaired in both hyperthyroidism and hypothyroidism, 
resulting in infertility, which will be corrected by restoration of the euthyroid 
state. Serum prolactin levels are increased in about 40% of patients with 
hypothyroidism, presumably a manifestation of increased TRH release; this will 
revert to normal with T4 therapy.. 
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               PHYSIOLOGIC CHANGES IN THYROID FUNCTION 
 
THYROID FUNCTION IN THE FETUS 
                         Prior to the development of independent fetal thyroid function, 
the fetus is dependent on maternal thyroid hormones for early neural 
development. However, by the 11th week of gestation, the hypophysial portal 
system has developed, and measurable TSH and TRH are present. At about the 
same time, the fetal thyroid begins to trap iodine. The secretion of thyroid 
hormone probably begins in mid gestation (18–20 weeks). TSH increases 
rapidly to peak levels at 24–28 weeks, and T4 levels peak at 35–40 weeks. T3 
levels remain low during gestation; T4 is converted to rT3 by type 3 5-
deiodinase during fetal development. At birth, there is a sudden marked rise in 
TSH, a rise in T4, a rise in T3, and a fall in rT3. These parameters gradually 
return to normal over the first month of life. 
THYROID FUNCTION IN PREGNANCY 
                           The striking change in thyroid parameters during pregnancy is 
the rise in TBG and consequent rise in total T4 and total T3 in the serum. The 
rise in TBG is due to estrogen-induced hepatic glycosylation of TBG with N-
acetylgalactosamine, which prolongs the metabolic clearance rate of TBG. 
There is usually no change in thyroxine-binding prealbumin and little change in 
albumin. Although total T4 and T3 are increased, a new equilibrium develops 
between free and bound thyronines, and the levels of free T4 and free T3 are 
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normal. Other changes in pregnancy include an increase in iodide clearance, 
which, in areas of low iodine intake, may result in impaired hormone synthesis 
and a fall in T4, a rise in TSH, and thyroid enlargement. hCG, which peaks near 
the end of the first trimester, has a weak TSH agonist activity and may be 
responsible for the slight thyroid enlargement that occurs at that time. Maternal 
I- crosses the placenta and supplies the fetal requirement; in large amounts, I- 
can inhibit fetal thyroid function. Maternal TSH-R Ab [stim] and TSH-R Ab 
[block] can also cross the placenta and may be responsible for thyroid 
dysfunction in the fetus. As noted above, most maternal T3 and T4 are 
deiodinated by placental type 3 5-deiodinase and do not reach the fetus.  
However, antithyroid drugs such as propylthiouracil and methimazole do cross 
the placenta and in large doses will block fetal thyroid function. 
CHANGES IN THYROID FUNCTION WITH AGING 
                              Thyroxine turnover is highest in infants and children and 
gradually falls to adult levels after puberty. The T4 turnover rate is then stable 
until after age 60, when it again drops slightly. Thus, replacement doses of 
levothyroxine will vary with age and other factors, and patients taking the drug 
must be monitored regularly. 
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EFFECTS OF ACUTE & CHRONIC ILLNESS ON THYROID FUNCTION 
(EUTHYROID SICK SYNDROME) 
                    Acute or chronic illness may have striking effects on circulating 
thyroid hormone levels by modifying the peripheral metabolism of T4 or by 
interference with T4 binding to TBG. These effects can be classified as            
(1) the low T3 syndrome or (2) the low T3-T4 syndrome. 
                   Inhibition of outer ring type 1 5′-deiodinase or activation of type 3 
5-deiodinase accelerates conversion of T4 to rT3 and conversion of T3 to 3,3′-T2. 
These reactions will markedly lower the circulating level of T3, resulting in the 
low T3 syndrome. This occurs physiologically in the fetus and pathologically in 
circumstances of carbohydrate restriction, as in malnutrition, starvation, 
anorexia nervosa, and diabetes mellitus, and in patients with hepatic disease or 
major acute or chronic systemic illnesses. Drugs that inhibit type 1 5′-
deiodinase also lower the circulating levels of T3; corticosteroids, amiodarone, 
and iodinated dyes are the most effective, and propylthiouracil and propranolol 
are relatively weak. The pathogenesis of the low T3 syndrome when associated 
with acute or chronic illness is thought to involve cytokines such as tumor 
necrosis factor, secreted by inflammatory cells, which inhibit type 1 5′-
deiodinase, accelerating inner ring deiodination of T4. 
                      T3 levels are low; total T4 levels are normal or slightly elevated; 
free T4 often is slightly elevated; and rT3 is elevated. TSH is normal. True 
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hypothyroidism can be ruled out by the normal T4, FT4, and TSH and by the 
elevated rT3. 
                    Patients with the low T3-T4 syndrome are usually much sicker, and 
indeed the mortality rate in this group of patients may approach 50%. Serum T3 
and T4 levels are both low; FT4 is usually normal; and rT3 is elevated. TSH is 
usually normal, though it may be low if the patient is receiving dopamine or 
corticosteroids, which suppress TSH. The pathogenesis of this syndrome is 
thought to involve the liberation of unsaturated fatty acids, such as oleic acid, 
from anoxic or injured tissue, which inhibits the binding of T4 to TBG. The 
syndrome can be differentiated from true hypothyroidism by the normal levels 
of free T4 and TSH. 
               These abnormalities normalize when the patient recovers. Recovery is 
frequently accompanied by a transient elevation of the serum TSH that may be 
misinterpreted as hypothyroidism. In this setting, in the absence of clinically 
apparent hypothyroidism, it is best to avoid thyroid hormone therapy and to 
reevaluate at a later time following recovery. It is possible that intracellular 
hypothyroidism exists in these patients, but administration of T3 or T4 does not 
benefit the patient and may worsen the situation. Thus, these changes may 
represent a protective adaptation on the part of the organism to severe illness. 
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                               TESTS OF THYROID FUNCTION 
 
The function of the thyroid gland may be evaluated in many different ways:  
(1) blood level of thyroid hormones,  
(2) study of the hypothalamic-pituitary-thyroid axis,  
(3) evaluation of iodine metabolism,  
(4) gland size measurement,  
(5) biopsy of gland ,  
(6) action on peripheral tissues by thyroid hormone, 
(7) magnitude of thyroid autoantibodies. 
TESTS OF THYROID HORMONES IN BLOOD 
                       The total serum T4 and total serum T3 are measured by 
radioimmunoassay or immunofluorescent assay. If the concentration of serum 
thyroid hormone binding proteins is normal, these measurements provide a 
reasonably reliable index of thyroid gland activity. However, changes in serum 
concentration of thyroid-binding proteins or the presence of drugs that modify 
the binding of T4 or T3 to TBP will modify the total T4 and T3 but not the 
amount of free hormone. Thus, further tests must be performed to assess the 
free hormone level that determines biologic activity. 
                      Serum free thyroxine (FT4) can be estimated using the free 
thyroxine index (FT4I). This is the product of the total T4 multiplied by the 
percentage of free T4 as estimated by the amount of T4 which binds to resin or 
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charcoal added to the system. A more precise estimate of free thyroxine is 
obtained by a two-step chemiluminescent immunoassay in which the thyroxine 
antibody system is modified to react with the free hormone. The normal range 
for FT4 by this assay is 0.7–1.85 ng/dL (9–24 pmol/L). Although the FT4I or the 
FT4 is valid for normal subjects, these assays may not be valid in subjects with 
dysproteinemias and abnormal thyroxine-binding proteins (TBPs)—or in 
subjects taking medications modifying TBP or in subjects with the euthyroid 
sick syndrome. In these subjects, free thyroxine by equilibrium dialysis (FT4D) 
will more accurately reflect the level of free thyroxine. Note that FT4 does not 
measure T3, so that patients receiving high oral doses of T3 or with T3 
hyperthyroidism , FT4 may be low despite the hyperthyroid state (T3 toxicosis). 
Antiepileptic drugs such as phenytoin and carbamazepine and the 
antituberculous drug rifampin increase hepatic metabolism of T4, resulting in a 
low total T4, a low free T4, and a low FT4I. However, serum T3 and serum TSH 
levels are normal, indicating that patients receiving these drugs are euthyroid.  
T4 and FT4I may be low in severe illness, but FT4D and TSH are usually 
normal, which will distinguish these very ill patients from patients who are 
hypothyroid. 
               At times, FT4I and FT4D will be inappropriately elevated. For 
example, drugs such as iodinated contrast media, amiodarone, glucocorticoids, 
and propranolol inhibit type 1 5′-deiodinase and the conversion of T4 to T3 in 
peripheral tissues, resulting in elevation of total T4, FT4I, and FT4D and 
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depression of T3. Hyperthyroidism is ruled out by the low T3 and normal TSH. 
FT4I and FT4D are inappropriately elevated in the rare syndrome of generalized 
resistance to thyroid hormone . The presence of heparin in serum, even in the 
tiny amounts that would be found in a patient with a “heparin lock” indwelling 
intravenous catheter, will cause a spurious increase in FT4D. This occurs in the 
test tube, since heparin activates lipoprotein lipase, releasing free fatty acids that 
displace T4 from TBG. 
Total T3 can be measured in serum by immunoassay with specific T3 antisera. 
The normal range in adults is 70–132 ng/dL (1.1–2 nmol/L). The measurement 
of total T3 is most useful in the differential diagnosis of hyperthyroidism, 
because T3 is preferentially secreted in early Graves' disease or toxic nodular 
goiter. In hyperthyroidism, this ratio will usually be well over 20, and it will be 
even higher in T3 thyrotoxicosis. T3 levels are often maintained in the normal 
range in hypothyroidism because TSH stimulation increases the relative 
secretion of T3; thus, serum T3 is not a good test for hypothyroidism. 
                T3 is bound to TBG, and the total T3 concentration in serum will vary 
with the level of TBG. Serum free T3 (FT3) can be measured by immunoassay 
or more precisely by equilibrium dialysis; the normal adult FT3 is 230–420 
pg/dL (3.5–6.5 pmol/L). 
              Reverse T3 (rT3) can be measured by radioimmunoassay. The serum 
concentration of rT3 in adults is about one-third of the total T3 concentration, 
with a range of 25–75 ng/dL (0.39–1.15 nmol/L). RT3 can be used to 
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differentiate chronic illness from hypothyroidism because rT3 levels are 
elevated in chronic illness and low in hypothyroidism. However, this 
differential diagnosis can be made by determination of TSH (see below), so that 
it is rarely necessary to measure rT3. 
Thyroglobulin(Tg) can be measured in serum by double antibody 
radioimmunoassay. The normal range will vary with method and laboratory, but 
generally the normal range is less than 40 ng/mL (< 40 µg/L) in the euthyroid 
individual and less than 2 ng/mL (< 2 µg/L) in a totally thyroidectomized 
individual. The major problem with the test is that endogenous thyroglobulin 
antibodies interfere with the assay procedure and, depending on the method, 
may result in spuriously low or spuriously high values. Serum thyroglobulin is 
elevated in situations of thyroid overactivity such as Graves' disease and toxic 
multinodular goiter; in subacute or chronic thyroiditis, where it is released as a 
consequence of tissue damage; and in patients with large goiters, in whom the 
thyroglobulin level is proportionate to the size of the gland. Serum 
thyroglobulin determinations have been most useful in the management of 
patients with papillary or follicular thyroid carcinoma. Following thyroidectomy 
and 131I therapy, thyroglobulin levels should be very low. In such a patient, 
serum thyroglobulin greater than 2 ng/dL (> 2 µg/L) indicates the presence of 
metastatic disease, and a rise in serum thyroglobulin in a patient with known 
metastases indicates progression of the disease. 
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EVALUATION OF THE HYPOTHALAMIC-PITUITARY-THYROID AXIS 
                         It has not been clinically feasible to measure TRH in the 
peripheral circulation in humans. However, very sensitive methods for the 
measurement of TSH have been developed using monoclonal antibodies against 
human TSH. The general principle is this: One monoclonal TSH antibody is 
fixed to a solid matrix to bind serum TSH, and a second monoclonal TSH 
antibody labeled with isotope or enzyme or fluorescent tag will bind to a 
separate epitope on the TSH molecule. The quantity of TSH in the serum is thus 
proportionate to the quantity of bound second antibody. The earlier TSH 
radioimmunoassays, which could detect about 1 µU of TSH/mL, were adequate 
for the diagnosis of elevated TSH in hypothyroidism but could not detect 
suppressed TSH levels in hyperthyroidism. The “second generation” of 
“sensitive” TSH assays, using monoclonal antibodies, can detect about 0.1 
µU/mL, and the “third generation” of “supersensitive” assays are sufficiently 
sensitive to detect about 0.01 µU/mL. This has allowed measurement of TSH 
well below the normal range of 0.5–5 µU/mL (0.5–5 mU/L) and has enabled the 
clinician to detect partially and totally suppressed serum TSH levels. The level 
of FT4 is inversely related to the logarithm of the TSH concentration . Thus, a 
small change in FT4 may result in a large change in TSH.  Serum TSH below 
0.1 µU/mL (0.1 mU/L) and an elevated FT4 or FT4I is indicative of 
hyperthyroidism. This may be due to Graves' disease, toxic nodular goiter, or 
high-dose thyroxine therapy. In the rare case of hyperthyroidism due to a TSH-
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secreting pituitary tumor, FT4I or FT4 will be elevated and TSH will not be 
suppressed but will actually be normal or slightly elevated. An elevated TSH (> 
10 µU/mL; 10 mU/L) and a low FT4 or FT4I is diagnostic of hypothyroidism. In 
patients with hypothyroidism due to a pituitary or hypothalamic tumor (central 
hypothyroidism), FT4I or FT4 will be low and TSH will not be elevated. This 
diagnosis can be confirmed by demonstrating the failure of serum TSH to 
increase following an injection of TRH. The TRH test is performed as follows: 
200 µg of TRH is administered intravenously. Serum TSH is measured before 
to the injection and after half an hour and an hour afterward. The absence of a 
rise in TSH indicates either pituitary insufficiency or suppression. A modest or 
delayed rise may be seen in patients with hypothalamic disease and 
hypothyroidism. The test can also be used to differentiate the 
hyperthyroxinemia of the T3 resistance syndrome from thyrotoxicosis due to a 
TSH-secreting pituitary tumor. TRH will produce a rise in TSH in the patient 
with a thyroid hormone resistance syndrome, whereas TSH-secreting tumors 
will not respond to TRH. Note that corticosteroids and dopamine inhibit TSH 
secretion , which will modify the interpretation of serum TSH levels in patients 
taking these drugs. 
                Serum TSH levels reflect the anterior pituitary gland sensing the level 
of circulating FT4. High FT4 levels suppress TSH and low FT4 levels increase 
TSH release. Thus, the ultrasensitive measurement of TSH has become the most 
sensitive, most convenient, and most specific test for the diagnosis of both 
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hyperthyroidism and hypothyroidism. Indeed, a suppressed TSH correlates so 
well with impaired pituitary response to TRH that the simple measurement of 
serum TSH has replaced the TRH test in the diagnosis of hyperthyroidism. 
IODINE METABOLISM & BIOSYNTHETIC ACTIVITY 
                     Radioactive iodine allows assessment of the turnover of iodine by 
the thyroid gland in vivo. Iodine-123 is the ideal isotope for this purpose: It has 
a half-life of 13.3 hours and releases a 28-keV x-ray and a 159-keV gamma 
photon but no beta emissions. Thus, it is easily measured and causes little tissue 
damage. It is usually administered orally in a dose of 100–200 µCi, and 
radioactivity over the thyroid area is measured with a scintillation counter at 4 
or 6 hours and again at 24 hours . The normal radioactive iodine uptake (RAIU) 
will vary with the iodide intake. In areas of low iodide intake and endemic 
goiter, the 24-hour RAIU may be as high as 60–90%. In hyperthyroidism due to 
Graves' disease or toxic nodular goiter, the 24-hour radioactive iodine uptake is 
markedly elevated, though if the iodide turnover is very rapid, the 5-hour uptake 
may be even higher than the 24-hour uptake.  
                     Thyrotoxicosis with a very low thyroidal RAIU occurs in the 
following situations: (1) in subacute thyroiditis; (2) during the active phase of 
Hashimoto's thyroiditis, with release of preformed hormone, causing 
“spontaneously resolving thyrotoxicosis”; (3) in thyrotoxicosis factitia due to 
oral ingestion of a large amount of thyroid hormone; (4) as a result of excess 
iodide intake (eg, amiodarone therapy), inducing thyrotoxicosis in a patient with 
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latent Graves' disease or multinodular goiter, the low uptake being due to the 
huge iodide pool; (5) in struma ovarii; and (6) in ectopic functioning metastatic 
thyroid carcinoma after thyroidectomy. 
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THYROID IMAGING 
1. RADIONUCLIDE IMAGING 
                123I and technetium Tc 99m pertechnetate (99mTc as TcO4) are useful for 
determining the functional activity of the thyroid gland. 123I is administered 
orally in a dose of 200–300 µCi, and a scan of the thyroid is obtained at 8–24 
hours. 99mTcO4 is administered intravenously in a dose of 1–10 mCi, and the 
scan is obtained at 30–60 minutes. Images can be obtained with either a 
rectilinear scanner or a gamma camera. The rectilinear scanner moves back and 
forth over the area of interest; it produces a life-size picture, and special areas, 
such as nodules, can be marked directly on the scan . The gamma camera has a 
pinhole collimator, and the scan is obtained on a fluorescent screen and 
recorded on Polaroid film or a computer monitor. The camera has greater 
resolution, but special areas must be identified with a radioactive marker for 
clinical correlation . Radionuclide scans provide information about both the size 
and shape of the thyroid gland and the geographic distribution of functional 
activity in the gland. Functioning thyroid nodules are called “hot” nodules, and 
those not functioning  are stated “cold” nodules. The malignancy accounts only 
less tthan 1% as hot nodules and they turn into toxic and cause thyrotoxicosis. . 
Among cold nodules 16% were malignant. Occasionally, a nodule will be hot 
with 99mTcO4 and cold with 
123I, and a few of these nodules have been 
malignant. 131I is the preferred isotope for huge substernal goiter & for distant 
metastases. 
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2. FLUORESCENT SCANNING 
               The iodine content can be determined and an image of the thyroid 
gland can be obtained by fluorescent scanning without administration of a 
radioisotope. An external source of americium-241 is beamed at the thyroid 
gland, and the resulting emission of 28.5 keV x-ray from iodide ions is 
recorded, producing an image of the thyroid gland similar to that obtained with 
123I. The advantage of this procedure is that the patient receives no radioisotope 
and the gland can be imaged even when it is loaded with iodine—as, for 
example, after intravenous contrast media. The disadvantage of this study is that 
it requires specialized equipment that may not be generally available. 
 
THYROID ULTRASONOGRAPHY OR MAGNETIC RESONANCE 
IMAGING 
                A rough estimate of thyroid size and nodularity can be obtained from 
radionuclide scanning, but much better detail can be obtained by thyroid 
ultrasonography or MRI. 
              USG of thyroid is helpful in finding the size of gland or nodular size 
and for assessment of treatment. It is helpful also for differentiating  cystic 
lesions from solid one. Substernal goiter cannot be assessed by USG. 
             MRI has more advanced technique and gives good picture of  thyroid 
gland, posterior or substernal extension pathology. Both transverse and coronal 
images of the gland can be obtained, and lymph nodes as small as 1 cm can be 
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visualized. MRI is not useful in tracheal compression from a huge goiter, 
tracheal invasion by  thyroid tumours, or metastases to lymph nodes. 
 
THYROID BIOPSY 
                 The best procedure for differentiating from benign and malignant 
disease is Fine-needle aspiration biopsy. It is a simple to perform and no 
admission required. The skin over the nodule is cleansed with alcohol, and, if 
desired, a small amount of 1% lidocaine can be injected intracutaneously for 
local anesthesia. A No. 25  3.75 cm needle is pierced in the gland and moved to 
and fro till a little quantity of blood comes in needle and it is taken out., and 
with a syringe the contents of the needle is put onto a sterile slide. A second 
clean slide is placed on top of the first slide, and a thin smear is obtained by 
drawing the slides apart quickly. Alternatively, a 10 mL or 20 mL syringe in an 
appropriate syringe holder can be used with a No. 23 one-inch needle to sample 
the nodule or to evacuate cystic contents. 
                Using Wright's or Giemsa's stain,  fixed in alcohol and  with 
Papanicolaou stain slides are fixed or made dry.The sensitivity (true-positive 
results divided by total cases of disease) is about 95%, and the specificity (true-
negative results divided by total cases of no disease) is also about 95%. For best 
results, fine-needle aspiration biopsy it needs a fair amount of sample and 
cytologist experience. 
 
52 
 
EFFECTS OF THYROID HORMONES ON PERIPHERAL TISSUES 
                       The definitive test of thyroid function would be a test of the effect 
of thyroid hormones on body tissues. Thyroid hormones increase heat 
production and oxygen consumption. A measurement of this basal oxygen in the 
intact organism became one of the first tests of thyroid function, the basal 
metabolic rate (BMR). However, this test is nonspecific and insensitive and is 
rarely used today. The speed of muscle stretching and relaxation is increased in 
hyperthyroidism and decreased in hypothyroidism. 
                      Cardiac muscle contractility can also be measured as an index of 
thyroid hormone action. With echocardiography, it is relatively easy to measure 
such indices as the preejection period (PEP), the time from onset of the QRS 
complex to the opening of the aortic valve; or the left ventricular ejection time 
(LVET). These are prolonged in hypothyroidism and shortened in 
hyperthyroidism. Although these measurements are modified by coexistent 
cardiac disease, they may be the best objective tests for measuring the 
peripheral effects of thyroid hormone action. 
                     Thyroid hormones influence the concentration of a number of 
enzymes and blood constituents. serum cholesterol is usually lowered in 
hyperthyroidism and elevated in hypothyroidism. Serum creatine kinase and 
lactic dehydrogenase, probably of skeletal muscle origin, are elevated in 
hypothyroidism and indeed, isoenzyme determination may be required to 
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differentiate the enzyme changes occurring in myocardial infarction from those 
occurring in myxedema. 
                     Sex hormone-binding globulin (SHBG) and angiotensin-
converting enzyme are also increased in hyperthyroidism and decreased in 
hypothyroidism. However, none of these biochemical or enzyme changes are 
sensitive or specific enough for diagnostic use. 
MEASUREMENT OF THYROID AUTOANTIBODIES 
                 Thyroid autoantibodies are 
(1) thyroglobulin antibody  
(2) thyroperoxidase antibody  
(3) TSH receptor antibody.  
                   Thyroglobulin antibody and Thyroperoxidase antibody will be 
found by using hemagglutination, enzyme-linked immunosorbent assay 
(ELISA), or radioimmunoassay (RIA). The hemagglutination technique is much 
less sensitive than the ELISA or RIA methods. The incidence of positive TPO 
antibodies in normal men (by hemagglutination) was low about 2% and did not 
increase with age. On the other hand, high Tg Ab and TPO Ab titers by RIA are 
found in 97% of patients with Graves' disease or Hashimoto's thyroiditis.                                                 
Thyroglobulin antibodies are often high early in the course of Hashimoto's 
thyroiditis and decrease with time; TPO antibodies are usually measurable for 
the life of the patient. The titers of both Tg and TPO antibodies will decrease 
with time following institution of T4 therapy in Hashimoto's thyroiditis or with 
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antithyroid therapy in Graves' disease. A strongly positive test for either of these 
antibodies is an indication of the presence of autoimmune thyroid disease but is 
not specific for the type of disease, ie, hyperthyroidism, hypothyroidism, or 
goiter. 
                       The thyroid receptor stimulating antibody (TSH-R Ab) is 
characteristic of Graves' disease. It was originally measured by demonstrating 
prolonged discharge of radioiodine from the thyroid gland of the mouse after 
injection of serum from a patient with Graves' disease; it was then called long-
acting thyroid stimulator (LATS). This laborious assay was now outdated and 
bioassay was being used using hamster ovary cells. Next, the rise in  cAMP of 
thyroid is evaluated by incubation with serum or IgG. The results was positive 
in 80–90% of patients with Graves' disease and undetectable in healthy subjects 
or patients with Hashimoto's thyroiditis (without ophthalmopathy), nontoxic 
goiter, or toxic nodular goiter. It is most useful for the diagnosis of Graves' 
disease in patients with euthyroid ophthalmopathy or in predicting neonatal                
Graves' disease in the newborn of a mother with active or past Graves' disease. 
 
                   The same type of assay can be used to detect TSH receptor-blocking 
antibody. In this assay, the increase in cAMP induced by TSH added to a human 
thyroid cell culture or the culture of hamster ovary cells containing the TSH-R 
gene is blocked by concurrent incubation with the patient's serum. The TSH-
binding inhibition assay (TBII) measures the ability of serum IgG to inhibit the 
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binding of labeled TSH to a thyroid cell membrane preparation containing the 
TSH receptor. This technique is not as satisfactory as the bioassay because there 
are a variety of nonspecific interfering substances, such as thyroglobulin, which 
inhibit TSH binding. However, a modification of the TSH-binding inhibition 
assay using recombinant human TSH receptor has proved to be more reliable. 
Detection of a TSH receptor-blocking antibody in maternal serum may be very 
helpful in predicting the occurrence of congenital hypothyroidism in newborns 
of mothers with autoimmune thyroid disease. 
SUMMARY: CLINICAL USE OF THYROID FUNCTION TESTS 
                       The diagnosis of thyroid disease has been greatly simplified by 
the development of sensitive assays for TSH and free thyroxine. The estimate of 
free thyroxine, either FT4I or FT4, and a sensitive TSH determination are used 
both for the diagnosis of thyroid disease and for following patients receiving T4 
replacement or antithyroid drug therapy. An elevated TSH and low free 
thyroxine establish the diagnosis of hypothyroidism, and a suppressed TSH and 
elevated FT4 establish the diagnosis of hyperthyroidism. 
                       Other tests are available for special uses. In hypothyroidism, Tg 
Ab or TPO Ab tests will clarify the cause of the illness, and in hyperthyroidism 
elevation of free T3, abnormal radioiodine uptake and scan, and a positive test 
for TSH-R Ab] may be useful. In patients with nodules or goiter, fine-needle 
aspiration biopsy will rule out malignancy; radioiodine scan may help to 
determine function; and thyroid ultrasound or MRI may be helpful in following 
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the size or growth of the goiter. Patients with known thyroid cancer are 
followed with serial thyroglobulin determinations, and 131I scan or MRI may be 
useful for detection of metastatic disease. 
 
 
                     HYPERTHYROIDISM & THYROTOXICOSIS 
 
Hyperthyroidism is one condition where excess amount of thyroid hormone is 
synthesized.Thyrotoxicosis is a clinical diagnosis due to tissue exposure to high 
levels of thyroid hormone in blood. Sometimes it may be arise due to over 
intake of hormone or ectopic site production.  
The various forms of thyrotoxicosis are 
1. DIFFUSE TOXIC GOITER (GRAVES' DISEASE) 
Graves' disease is the most common form of thyrotoxicosis and may occur at 
any age, more commonly in females than in males. The syndrome consists of 
one or more of the following features: (1) thyrotoxicosis, (2) goiter,  
(3) ophthalmopathy (exophthalmos), and (4) dermopathy (pretibial myxedema). 
ETIOLOGY 
             Graves' disease is an autoimmune disease of unknown etiology. 
Nowadays it is suggested there is more hereditary risk of developing disease is 
around 15%. Females to male ratio is 5: 1 in developing disease and mean age 
of presentation would be 20 t0 40 years. 
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PATHOGENESIS 
                  In Graves' disease, T lymphocytes become activated  to antigens in 
the thyroid gland and activate B lymphocytes to produce antibodies.  One 
antibody is marked towards the TSH receptor site in the thyroid cell and has the 
ability to stimulate the thyroid cell to increased growth and function. The 
presence of this circulating antibody is positively correlated with active disease 
and with relapse of the disease. There is an strong hereditary predisposition, but 
still it’s a question of debate which triggers acute reaction. There are various 
factors that may aggravate the immune response like ,(1) pregnancy, especially 
after delivery; (2) iodide deficient areas ; (3) treatment with lithium; 
(4)infections; and (5) glucocorticoid stoppage.  
                The mechanism of ophthalmopathy is due to cytotoxic lymphocytes  
and cytotoxic antibodies acts against to a antigen  TSH-R present in orbital 
fibroblasts, orbital muscle, and thyroid tissue. Cytokines from these sensitized 
lymphocytes would cause inflammation of orbital fibroblasts and orbital 
myositis, resulting in enlarged orbital muscles, proptosis of the eye balls, and 
diplopia as well as redness, congestion, and conjunctival and periorbital edema. 
                  The pathogenesis of thyroid dermopathy (pretibial myxedema) and 
the rare subperiosteal inflammation on the phalanges of the hands and feet 
(thyroid osteopathy) it may also involve lymphocyte cytokine stimulation of 
fibroblasts in these locations. 
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                           PATHOGENESIS OF GRAVE’S DISEASE 
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CLINICAL FEATURES 
A. SYMPTOMS AND SIGNS 
                         In younger individuals, common manifestations include 
increased heart beat, anxiety, easy tiredness, increased movements, loose stools, 
increased sweating, heat intolerance,  increased  loss of weight with increase in 
loss of appetite. Swelling of gland,  eye signs , and mild high heart rate may be 
seen.  Muscle weakness and loss of muscle mass may be so severe that the 
patient cannot rise from a chair without assistance. In children, rapid growth 
with accelerated bone maturation occurs.  
                        In patients over age 60, cardiovascular and myopathic 
manifestations predominate; the most common presenting complaints are 
palpitation, dyspnea on exertion, tremor, nervousness, and weight loss. 
                     The eye signs of Graves' disease have been classified by Werner . 
This classification is useful in describing the extent of the eye involvement.  
The first letters of each class form the mnemonic “NO SPECS.”  
Class I involves upper lids spasm related with active thyrotoxicosis and 
subsides when thyrotoxicosis is controlled.   
Classes II-VI denote  infiltrative disease involving orbital muscles and orbital 
tissues.  
Class II is associated with involvement of soft tissue with periorbital edema, 
congestion and edema of the conjunctiva.  
Class III is proptosis found by the Hertel exophthalmometer.  
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Class IV consists of muscle involvement. The muscle most commonly involved 
in the infiltrative process is the inferior rectus, limiting upward gaze. Medial 
rectus is also affected so that lateral gaze is difficult. 
Class V is involvement of cornea.  
Class VI loss of vision from optic nerve involvement.  
                  Thyroid ophthalmopathy is because of  infiltration of  muscles of 
orbit with lymphocytes and edema fluid formed  because of inflammation.  
The orbit is a cone enclosed by bone, and swelling of the extraocular muscles 
within this closed space causing enlargement of the eyeball and restricted 
muscle movement, resulting in diplopia. Ocular muscle enlargement can be 
demonstrated by orbital CT scanning or MRI. When muscle swelling occurs 
posteriorly, toward the apex of the orbital cone, the optic nerve is compressed, 
which may cause loss of vision. 
                                      
                    EYE CHANGES IN THYROID OPHTHALMOPATHY 
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            CLASSIFICATION OF EYE CHANGES IN GRAVE’S DISEASE 
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            Thyroid dermopathy is skin thickening in legs because of increased 
glycosaminoglycans . Rare condition involving two to three per 100 persons 
having Graves' disease.  Often comes along with ophthalmopathy. TSH receptor 
antibody levels will be high.They will have hard skin and difficult to hold in 
hands. Sometimes the dermopathy involves the entire lower leg and may extend 
onto the feet. Bony involvement (osteopathy), with subperiosteal bone 
formation and swelling, is particularly evident in the metacarpal bones . This 
too is a relatively rare finding. A more common finding in Graves' disease is 
separateion of the fingernails from their beds, or onycholysis. 
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       GRAVE’S DERMOPATHY                   GRAVE’S OSTEOPATHY 
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B. LABORATORY FINDINGS 
                        Essentially, the combination of an increased free thyroxine T4 
and a decreased Thyroid stimulating hormone makes the diagnosis of 
hyperthyroidism. Ophthal signs are there, the diagnosis of Graves' disease is 
confirmed. Otherwise if absent, patient should undergo radioiodine uptake even 
in absence of goiter.  Increased uptake is conclusive of Graves' disease or toxic 
nodular goiter. Decreased  uptake is present in other hyperthyroid which is 
benign and thyroiditis. It can also be present in thyroxine treatment overload. 
Or,  rarely, in association with a struma ovarii. If both FT4 and TSH are elevated 
and radioiodine uptake is also elevated, consider a TSH-secreting pituitary 
tumor or generalized or pituitary resistance syndromes. If FT4 is normal and 
TSH is suppressed, check FT3, which will be elevated in early Graves' disease 
or in T3-secreting toxic nodules. Low FT3 will be found in the euthyroid sick 
syndrome or in patients receiving corticoids or dopamine. 
                     Thyroid autoantibodies Tg Ab and TPO Ab are usually present in 
both Graves' disease and Hashimoto's thyroiditis, but TSH-R Ab  is specific for 
Graves' disease. The 123I or technetium scan is useful to evaluate the size of the 
gland or the presence of “hot” or “cold” nodules. CT and MRI scans of the orbit 
have reveales muscle enlargement in most patients with Graves' disease even 
when there is no clinical evidence of ophthalmopathy. 
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DIFFERENTIAL DIAGNOSIS 
                          Graves' disease wont present in its usual manner. It can present 
with unlikely form where diagnosing is difficult. significant muscle wasting 
signifies severe myopathy. Thyrotoxic periodic paralysis is rare form and will 
have a sudden attack of flaccid paralysis and hypokalemia. The paralysis 
subsides naturally and can be prevented by potassium treatment and beta 
blockers. The illness is cured by appropriate treatment of the thyrotoxicosis.          
Patients with thyrocardiac disease present primarily with symptoms of heart 
involvement especially refractory atrial fibrillation insensitive to digoxin or 
with high-output heart failure.  Half the number of patients have no previous 
heart problems and are reversed once treated thyrotoxicosis. In  few aged 
patients will present with loss of weight , tiny goiter , decreased atrial 
fibrillation, and severe depression, with no evidence increased catecholamine 
reactivity. These placid patients have “apathetic hyperthyroidism.” Finally, 
some young women may present with amenorrhea or infertility as the primary 
symptom.  In all of these instances, the diagnosis of hyperthyroidism can 
usually be made on the basis of the clinical and laboratory studies. 
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   LABORATORY TESTS FOR  DIAGNOSIS OF HYPERTHYROIDISM 
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COMPLICATIONS 
  
                  Thyrotoxic crisis is medical emergency presenting with more 
poronounced clinical features of thyrotoxicosis. More commonly, it follows 
after a surgery, radioactive iodine therapy, or during a severe, stressful illness or 
disorder like uncontrolled diabetes, trauma, acute infection, severe drug 
reaction, or myocardial infarction.  
                 The clinical features is due to increased metabolism and more 
adrenergic surge. High grade fever with increased sweating and flushing will be 
there. There is marked tachycardia, often with atrial fibrillation and high pulse 
pressure and occasionally with heart failure. Central nervous system symptoms 
include marked agitation, restlessness, delirium, and coma. Gastrointestinal 
symptoms include nausea, vomiting, diarrhea, and jaundice. A fatal outcome 
will be associated with heart failure and shock. 
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                           TREATMENT OF GRAVES' DISEASE 
 
   Three modes of treatment 
 (1) antithyroid drug therapy 
 (2) surgery  
 (3) radioactive iodine therapy. 
A. ANTITHYROID DRUG THERAPY 
                      In general, antithyroid drug therapy is most useful in young 
patients with small glands and mild disease. The drugs propylthiouracil or 
methimazole are given until the disease undergoes spontaneous 
remission.Treatment period varies fromed for 6 months to 15 years. This mode 
of treatment has increased relapse rate. Antithyroid drugs usually started in high 
doses till patient becomes euthyroid, then maintenance therapy achieved. A 
common regimen consists of giving propylthiouracil, 100 mg every 6 hours 
initially, and then in 4–8 weeks reducing the dose to 50–200 mg once or twice 
daily. Propylthiouracil has one advantage over methimazole by inhibiting the 
T4 conversion to T3. Me-thimazole has a longer duration of action and is more 
useful if a single daily dose is desirable. FT4 and TSH are used in assessment of 
treatment. 
                   An alternative method of therapy is combination of methimazole 
with levothyroxine to prevent hypothyroidism. 
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 Duration of therapy—The duration of therapy with antithyroid drugs in 
Graves' disease ranges from 6 months to 20 years . A sustained remission 
may be predicted in about 80% of treated patients in the following 
circumstances: (1) if the thyroid gland reverts to normal size; (2) if the 
disease can be suppressed with little dose of antithyroid drugs; (3) TSH-R 
Ab is should be no longer detectable in the serum. 
 
B. SURGICAL TREATMENT 
                            For large glands and MNG , subtotal thyroidectomy is done. 
The patient should be made euthyroid before surgery. Potassium iodide given 
before two weeks of surgery to reduce vascularity. There is still a debate in 
leaving how much thyroid tissue back. Most of them need postop thyroxine 
supplementation. Complications like nerve injury can occur. 
 
C. RADIOACTIVE IODINE THERAPY 
                       In old aged patients and in whom preexisting heart disease or 
other medical problems, severe thyrotoxicosis, ideal thing is to attain euthyroid 
state before therapy. For this , pretreatment with methimazole is given . Because 
it is usually desirable to destroy most of the gland in patients with underlying 
medical problems, the dose of 131I may be slightly larger than is ordinarily 
given. 
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                          Major adverse effect of this therapy is hypothyroidism and it 
will be present in 80% of cases. They can be treated with thyroxine replacement 
therapy.  Hypothyroidism may occur after any type of therapy for Graves' 
disease even after antithyroid drug therapy; in some patients, “burned-out” 
Graves' disease may be an end result of autoimmune thyroid disease. 
                           Acordingly, all patients with Graves' disease require lifetime 
follow-up to be certain that they remain euthyroid. 
D. OTHER MEDICAL MEASURES 
     1,In acute phase, beta-adrenergic blockers are used. Propranolol, 10–40 mg     
6th hourly, will control heart rate, blood pressureand arrhythmia.  
     2,Adequate nutrition, including multivitamin supplements, is essential.  
     3,Barbiturates increases T4 metabolism, and phenobarbital used. 
     4,Ipodate sodium or iopanoic acid has been shown to inhibit both thyroid 
hormone synthesis and release and peripheral conversion of T4 to T3. 
      5,Cholestyramine, 4 g orally three times daily, will decreases serum T4 by 
binding it in the intestine. 
                      In a patient with a large toxic goiter and a severe allergic reaction 
to antithyroid drugs, ipodate sodium and beta blockade can be used effectively 
as preparation for surgery. 
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OTHER CAUSES OF HYPERTHYROIDISM 
TOXIC ADENOMA 
                   A  adenoma secrets more T3 and T4 will cause hyperthyroidism. It is 
usually a “hot nodule” , gradually the size grows and masks the other part of the 
gland. Senior members are vulnerable. Routine hyperthyroid clinical features 
are seen. ophthalmopathy will be absent. On palpation nodule is seen with less 
thyroid tissue.TSH levels will be low and increase in T3 . Toxic adenomas are  
always benign and follicular. Treated  by using  antithyroid drugs,radioactive 
iodine or unilateral lobectomy. 
TOXIC MULTINODULAR GOITER 
                  This is similar to toxic adenoma except radioiodine scan shows 
multiple functioning nodules. 
SUBACUTE OR CHRONIC THYROIDITIS 
                      Subacute or chronic, may present with an acute release of T4 and 
T3, producing symptoms of mild to severe thyrotoxicosis. These illnesses can be 
differentiated from other forms of thyrotoxicosis in that the radioiodine uptake 
is markedly suppressed, and the symptoms usually subside spontaneously over a 
period of weeks or months. 
THYROTOXICOSIS FACTITIA 
                   This is a psychoneurotic disturbance in which the patient ingests 
excessive amounts of thyroxine or thyroid hormone, usually for purposes of 
weight control. Psychotherapy is used. 
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                 CARDIOVASCULAR CHANGES IN HYPERTHYROID 
 
o Increased  Myocardial contractility 
o Increased Cardiac output 
o Increased Systolic/diastolic function 
o Increased Systolic blood pressure 
o Increased Blood volume 
o Increased Venous resistance 
o Decreased Arterial resistance 
o Decreased Diastolic blood pressure 
o Tachycardia at rest 
o Systolic murmur 
o Mitral valve prolapse 
o Loud First heart sound 
o Possible third heart sound 
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                    CARDIOVASCULAR CHANGES IN HYPERTHYROID 
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ELECTROCARDIOGRAPHIC FEATURES OF THYROTOXICOSIS: 
Most common findings include; 
                       • Sinus tachycardia 
                       • Increased QRS voltages 
                       • Atrial fibrillation 
 
Other findings are; 
 Non-specific ST and T wave changes. 
 Supraventricular arrhythmias which includes, 
o premature atrial beats 
o paroxysmal supraventricular tachycardia 
o multifocal atrial tachycardia 
o  atrial flutter. 
 Ventricular extrasystoles 
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                                     AIMS AND OBJECTIVES 
 
 
1. To study the clinical profile of hyperthyroidism at Government 
Stanley hospital. 
 
           2. To study echocardiographic findings in these patients. 
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                                     MATERIALS AND METHODS 
 
PLACE OF STUDY: 
 
 DEPARTMENT OF GENERAL MEDICINE,  ENDOCRINOLOGY 
OPD, MEDICAL OPD, MEDICAL WARDS,   STANLEY MEDICAL 
COLLEGE AND HOSPITAL, CHENNAI. 
 
SAMPLE SIZE: 
                          60 
 
 
DURATION: 
 
 NOV 2013 TO NOV 2014. 
 
 
STUDY DESIGN: 
 
 PROSPECTIVE  OBSERVATIONAL STUDY 
 
ETHICAL COMMITTEE APPROVAL:  
            THE ETHICAL COMMITTEE APPROVAL WAS OBTAINED FOR 
THIS STUDY 
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PATIENT SELECTION: 
 
ANY PATIENT COMING WITH  SYMPTOMS SUGGESTIVE OF 
HYPERTHYROID TO ENDOCRINOLOGY OPD, MEDICAL OPD 
MEDICAL WARDS.  
 
EXCLUSION CRITERIA: 
 
 PATIENTS WITH  KNOWN HEART DISEASE.  
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                                                        CONSENT 
 
The study group thus identified by the above criteria (inclusion and exclusion 
criteria) was first instructed about the nature of the study. Willing participants 
were taken up for this study after getting a written / informed consent from these 
patients or their relatives in the local vernacular language. 
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STUDY SUBJECTS: 
 
All   the  patients  who  fulfilled  the  inclusion  criteria   of  any  age  and  both  
genders  were  included  in  this  study. The  included  patients were subjected to 
detailed history taking, complete physical examination  and  the  relevant  
laboratory  investigations  as per a proforma, exclusively  designed  for  the  study. 
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                         RESULTS, OBSERVATION, DISCUSSION 
 
The study includes total number of 60 patients. Data were collected and final 
analysis was made. 
 
ANALYSIS OF DATA OF STUDY GROUP 
AGE DISTRIBUTION: 
 
 
                                        Table1. Age distribution of study group 
 
Among 60 patients studied, most  patients were between the age group of 21 to 
30 years 27 ( 45 % ). Patients between 41 to 50 yrs were 11 ( 18%). Patients 
between 31-40 were 10 (17%). Followed by 6 patients were between 1 to 20 
years and above 51 years of age. They contribute to 10% of study group.  
 
AGE IN YRS NUMBER OF PATIENTS PERCENTAGE IN % 
1-20 6 10 
21-30 27 45 
31-40 10 17 
41-50 11 18 
51 & ABOVE 6 10 
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            Fig1 : Graph depicting age distribution in group 
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    Fig2:Pie chart depicting age distribution instudy group 
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SEX DISTRIBUTION IN STUDY GROUP: 
                             
                         Among 60 patients in study, most of them were females. Female 
group in the study were 56 and male were only 4. Females were 93% and males 
were 7%. So according to my study in Stanley hospital incidence of 
hyperthyroidism was more among females. 
  
                 
             Fig3:Graph depicting sex distribution in study group 
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                   Fig4:Pie chart showing sex distribution in study group 
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SEX AND MARITAL STATUS DISTRIBUTION IN STUDY 
GROUP 
 
 
Gender 
Married Unmarried No. of patients 
N % 
N 
% N % 
Male 3 75 1 25 4 
7 
Female 48 86 8 14 56 
93 
Total 51 80.5 
9 
19.5 60 
100 
                        
                         Table 2: Sex and Marital status distribution in study group  
 
 
 
 
In my study among 60 patients, 56 females and 4 were males. Out of these 56 
patients, most of them were married. 48 females were married and 8 were 
unmarried. Among male population 3 were married and 1 was unmarried.        
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86 % of females were married and 14% were married. While in males 75% were 
married and 25 % were unmarried. So in my study in Stanley hospital , 
incidence of hyperthyroid was more among female married patients. 
 
 
 
 
Fig5:Graph showing sex & marital status distribution in study group 
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SYMPTOM ANALYSIS DISTRIBUTION IN STUDY GROUP: 
 
 
         
             SYMPTOM ANALYSIS 
       
        NUMBR OF PATIENTS 
Neck swelling                      26 
Palpitation                      18 
Diarrhoea                       2 
Weight loss & increased appetite                      11 
Heat intolerance                       3 
Hair loss                      11 
Menstrual irregularities                      21 
Tremors                      12 
Diplopia & proptosis                       8 
  
          Table 3: Symptom analysis distribution in study group 
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        In clinical features distribution in my study group of 60 patients , most 
patients came with multiple complaints rather than single complaint. Neck 
swelling and menstrual irregularities leads the top followed by weight loss and 
increased appetite and hair loss ,diplopia least were diarrhea and heat 
intolerance. 
        
       Neck swelling is present in 26 patients, palpitation in 18 patients, menstrual 
irregularities in 21 patients , tremors in 12 patients, weight loss and increased 
appetite in 11 patients , diplopia & proptosis in 8 patients. Least were diarrhea 
in 2 patients and heat intolerance in 3 patients. 
       
       So according to my study in Stanley hospital, major complaint was neck 
swelling & menstrual irregularities. Least were diarrhea and heat intolerance. 
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     Fig6:Graph depicting symptom distribution in study group 
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        Fig7:Pie chart showing symptom distribution 
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Among 60 patients in study group, 40 members came with more than one 
symptoms that will be 67 %. Remaining 20 members alone had one symptom 
which will be 33%. 
 
 
 
 
     
                  
    
  
       Fig8:Pie chart showing number of symptom distribution 
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CLINICAL FINDINGS DISTRIBUTION IN STUDY GROUP: 
 
 
 
      CLINICAL SIGNS NUMBER OF PATIENTS PERCENTAGE % 
NORMAL    23 30 
GOITER               20             27 
TREMORS               13             17 
SINUS TACHYCARDIA               10             13 
EYE SIGNS               10             13 
  
       Table 4: Clinical findings distribution in study group 
 
 
 
 
 
In study group, clinical signs were various entities. Most of the patients were 
clinically normal without no signs. They were23 patients and contribute to 30 % 
Goiter is seen in 20 patients , which is 27 %, tremors were found in 13 patients 
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that is 17 %, sinus tachycardia and eye signs like lid lag sign, lid retraction  etc 
were seen in 10 patients , about 13 %. 
So according to my study, 30% were clinically normal and most common sign 
was goiter. 
                   
     Fig9:Graph depicting clinical signs distribution in study group 
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  Fig10: Pie chart showing clinical sign distribution in study group 
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According to my study, in Stanley 38% were clinically had no signs, 40 % were 
having single findings. Remaining 22% had more than one findings.  
 
 
 
 
 
 
       Fig11:Graph showing findings distribution in study group 
 
 
 
23
24
13
0 5 10 15 20 25 30
NO FINDINGS
SINGLE FINDING
MULTIPLE FINDIGS
96 
 
TSH DISTRIBUTION IN STUDY GROUP: 
       
              All 60 patients were tested for thyroid function and thyroid 
stimulating hormone levels were analysed. All of them showed TSH of low 
range, which depicted all patients were primary hyperthyroid and no secondary 
hyperthyroid cases in Stanley hospital. 
 
 
                 
 
 
         Fig12:Pie chart showing TSH distribution in study group 
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USG NECK FINDINGS DISTRIBUTION IN STUDY GROUP: 
 
             In study , all patients undergone ultra sound of neck to see the anatomy 
of the thyroid. Of these findings 37 persons had normal findings which is 62 %, 
Nodular goiter were found in 12 persons which is 20% and diffuse thyromegaly 
in 11 patients , that is 18%. 
             So according to my study, normal thyroid anatomy in ultrasound neck is 
present in Stanley hospital. 
 
 
 
USG NECK FINDINGS NUMBER OF 
PATIENTS 
PERCENTAGE % 
NORMAL           37             62 
NODULAR GOITRE           12             20 
THYROMEGALY            11             18 
 
        Table5: USG neck finding distribution in study group 
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     Fig13:Pie chart showing USG finding distributionn in study 
group 
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FNAC FINDING DISTRIBUTION IN STUDY GROUP: 
 
           FNAC analysis was done among study group. Out of 60 cases cystic 
degeneration was present in 37 patients, that is 62%. Colloid goiter present in 
13 patients , i.e. 22% and thyroiditis in around 10 persons which is 16%, mosly 
of hashimoto thyroiditis. 
          Cystic degeneration is the most common incidence in Stanley hospital. 
 
 
 
 
 
FNAC FINDINGS NUMBER OF 
PATIENTS 
PERCENTAGE % 
CYSTIC DEGENERATION               37                62 
COLLOID GOITRE               13                22 
THYROIDITIS               10                16 
 
 
          Table 6 : FNAC findings distribution in study group 
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       Fig14:Graph showing FNAC findings distribution in study 
                   group. 
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ANTIBODIES RESULTS DISTRIBUTION IN STUDY GROUP: 
 
            Out of 60 patients , 42 had normal Anti TPO & Anti Microsomal 
antibodies, which is 70% and 18 members had elevated antibody levels that is 
30%. 
 
 
                   
 
 Fig15: Pie chart showing antibodies results distribution in study 
             group  
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ECHOCARDIOGRAPHIC FINDINGS DISTRIBUTION IN 
STUDY GROUP: 
 
 
    
ECHO FINDINGS NUMBER OF PATIENTS PERCENTAGE % 
NORMAL               52               86.6 
SYSTOLIC DYSFUNCTION                2               3.3 
DIASTOLIC DYSFUNCTION                1               1.6 
REGURGITANT LESION                1               1.6 
CHAMBER ENLARGEMENT                2               3.3 
PULMONARY HYPERTENSION                2               3.3 
 
       Table 7 :ECHO findings distribution in study group 
 
 
 
                 Finally , echocardiogram was done in all 60 patients of the study 
group, 52 patients had normal echo with no abnormalities, which is 87% and 
remaining 8 (13%) had abnormal echo findings. 
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                Various abnormal echo findings are as follows, Systolic dysfunction 
was seen in 2 persons (3.3%), Chamber enlargement which is left ventricle in 2 
persons(3.3%), Pulmonary hypertension from mild to moderate in 2 
persons(3.3%), Diastolic dysfunction and Regurgitant lesion in mitral valve 
were seen in 1 person each(1.6%). 
                 So Echo findings in hyperthyroid were mostly normal except 8 cases 
in my study in  Stanley hospital. 
              
               
         Fig17:Pie chart shoeing Echo findings distribution in study 
                    group 
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 Fig 18: Pie chart shoeing Abnormal Echo findings distribution in 
             Study group 
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    Fig19:Graph  showing Abnormal Echo findings distribution in  
               Study group 
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1)A study was conducted by Babul H Reddy et al to find out the prevalence of 
pulmonary hypertension in hyperthyroidism.It was a prospective study which 
included 25 consecutive patients of hyperthyroidism was tested for pulmonary 
hypertension at baseline and after achieving euthyroid state.They were studied 
for LV function,cardiac output and trans mitral flow velocity.40% of patients had 
pulmonary hypertension and 16% pulmonary venous hypertension which was 
reversed through achievement of euthyroid state. 
2)A study conducted by Kahaly gj et al by using stress echocardiography on 
hyperthyroid patients and 42 patients were enrolled in the study.The stroke 
volume index,cardiac output, and ejection fraction were studied in the patients in 
hyperthyroid state, after treatment with propranolol and after achievement of 
euthyroid state.These parameters were substantially increased in hyperthyroid 
states and was blunted after propranolol treatment and reversed after achieving 
euthyroid state.Thus in hyperthyroidism the inotropic and chronotropic effects 
were increased which was reversed by achieving euthyroid state.   
3)RC Anakwue et al studied the effects of thyrotoxicosis and the incidence of 
congestive heart failure in black community.The study included 50 patients who 
were thyrotoxic and CCF was determined clinically and 
echocardiographically.The study revealed that CCF can be present in 
thyrotoxicosis in spite of hyperdynamic condition may be due to autoimmunity 
andcongestive circulation. 
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4)SM Ansari et al studied the effects hyperthyroidism on heart.Echocardiography 
was done on 69 patients on patients who had presented with palpitations an 
tremors and radioimmunoassay confirmed hyperthyroidism.47 patients had 
cardiac pathology.Atrial fibrillation was the most common pathology found in 
hyperthyroid patients. The results showed that thyroid hormones had positive 
inotropic and chronotropic effect and echocardiography play an important role in 
recognizing the pathology of the heart.                                       
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                                                CONCLUSION 
 
 Hyperthyroidism is more common in females of younger age group 
commonly in third decade of life. 
 Hyperthyroid patients mostly presents with neck swelling and palpitation 
and menstrual irregularities forms the significant complaint in my study. 
 Half of the patients had clinically no findings and some had multi nodular 
goiter, eye signs were present in ten percentage of them. 
 Hyperthyroid has significant effect on cardiac activity. It is a high output 
state. Causing systolic and diastolic dysfunction , pulmonary hypertension, 
left ventricle chamber enlargement , heart failure. 
 Hyperthyroidism-related cardiac changes was largely asymptomatic and 
reversible after restoration to an euthyroid state. So hyperthyroidism 
should be considered as the reversible cause in cardiac morbidity. 
 As a non-invasive method, echocardiography can play a vital role in 
recognizing the cardiac pathology in hyperthyroidism as well as to follow 
up the response to therapy. 
